DMPK and myotonic dystrophy type 1: Chloroquine (CQ), an inhibitor of autophagosome-lysosome fusion, is proposed for the treatment of myotonic dystrophy type 1 (DM1), a debilitating neuromuscular disease caused by the expansion of a CUG repeat in the 3′ UTR of the DMPK (DM1 protein kinase) pre-mRNA.